TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Patients Having Pulmonary Hypertension Associated With Sickle Cell Disease and Completing an ASSET Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA~* Completion of the 16-week treatment period in the double-blind ASSET study~* Women of childbearing potential must have a negative result on their serum pregnancy test and use reliable methods of contraception during study treatment and for 3 months after study treatment termination.~Reliable methods of contraception are:~1. Barrier type devices (e.g., female condom, diaphragm, contraceptive sponge) only in combination with a spermicide.~2. Intra-uterine devices.~3. Oral, injectable, transdermal or implantable contraceptives only in combination with a barrier method.~Hormone-based contraceptives alone, regardless of the route of administration, are not considered to be reliable methods of contraception.~Abstention, rhythm method, and contraception by the partner alone are not acceptable methods of contraception.~Women not of childbearing potential are defined as prepubescent, postmenopausal (i.e., amenorrhea for at least 1 year), or surgically or naturally sterile.~Signed written informed consent is obtained from the patient or patient's parent/ legal representative prior to initiation of any study-related procedure.~EXCLUSION CRITERIA~All patients (Groups A and B):~1. Any major protocol violation in the preceding double-blind ASSET study\*.~2. Hemoglobin concentration less than 6.0 g/dL.~3. Pregnancy or breast-feeding.~   \* Protocol violations will be reviewed by the monitor during site visits and discussed with the study staff on an ongoing basis and at the patient's completion of the double-blind study.~   Group B only:~4. Acute liver disease.~5. Newly diagnosed cirrhosis or portal hypertension.~6. ALT greater than or equal to 3 times ULN and/or albumin greater than 20% below LLN.~7. Newly diagnosed psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clarithromycin in Multiple Myeloma Induction Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Myeloma diagnosis according to IMWG criteria~* Treatment demanding disease~* High-dose melphalan with stem cell support scheduled as a part of the treatment~* Signed informed consent given prior to any study related activities~* Age \> 18 years~Exclusion Criteria:~* Allogeneic transplantation scheduled as a part of the treatment~* Myeloma treatment prior to entry in the study, except radiotherapy, bisphosphonates/denosumab or corticosteroids for symptom control~* Concurrent disease making clarithromycin treatment unsuitable~* Positive pregnancy test (only applicable for women with childbearing potential)~* Known or suspected hypersensitivity or intolerance to clarithromycin~* Prolonged QT corrected (QTc) interval ( \> 500 msec on screening ECG)~* Concurrent treatment with cabergoline, fluconazole, ketoconazole, pimozide, quetiapine, sirolimus, verapamil, tacrolimus, ergot alkaloid, simvastatin or other statins~* Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrolment, uncontrolled angina or known cardiac amyloidosis~* Severe renal dysfunction (estimated creatinine clearance \<10 mL/min)~* Serious medical or psychiatric illness which, in the judgment of the investigator, would make the patient inappropriate for entry into the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clarithromycin (Type: EXPERIMENTAL): Clarithromycin combined with VCD induction therapy
- Placebo (Type: PLACEBO_COMPARATOR): Placebo combined with VCD induction therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Acute Effects of Inhaled Treprostinil in Fontan Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients age 18 years and older~2. Single ventricle patients status post Fontan procedure~Exclusion Criteria:~1. Clinically unstable: these are patients who are experiencing new cardiovascular symptoms such as worsening shortness of breath, new onset arrhythmia, uncontrolled heart failure, or evidence of clinically significant cirrhosis or renal failure.~2. Evidence of Fontan pathway or intra cardiac obstruction as identified on prior clinically indicated imaging studies (echocardiography and MRI);~3. Evidence of left or right systemic ventricular systolic dysfunction with an Ejection fraction of \<40% on either echocardiogram or MRI from previously documented clinical data;~4. Presence of uncontrolled arrhythmias;~5. Unable to perform exercise testing for any reason or if deemed by the PI or designee that exercise testing would not be in the best interest of the participant~6. Currently pregnant and/or breastfeeding~7. Patient unable to provide informed consent~8. BMI \> 30 mg/m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treprostinil (Type: EXPERIMENTAL): A dose of 18mcg (3 breaths) will be administered using the Tyvaso® (treprostinil) inhalation system. Tyvaso® (treprostinil) inhalation solution is supplied in 2.9 mL clear ampules packaged as four ampules in a foil pouch. Frequency and duration- 3 times over 1 study visit.
- Placebo (Type: PLACEBO_COMPARATOR): A dose of 3 breaths of placebo will be administered using the Tyvaso® (treprostinil) inhalation system. Placebo will be supplies in matching ampules to treprostinil. Volume will match that of treprostinil. Frequency and duration- 3 times over 1 study visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oral Health Condition and Quality of Life in Children With Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who, based on the agreement of parents and/or guardians, agree to participate in the research with a signed Informed Consent Form~* Patients from 3 to 17 years of age~* Patients older than 6 years must not only have parental and/or guardian authorization must have the consent term~* Patients who have not started antineoplastic treatment~* Patients with ALL only with BFM protocol~* AML patients with BFM protocol only~Exclusion Criteria:~* Responsible for patients who do not sign the free and informed consent form.~* Patients under three years of age and over 17 years of age~* Children older than six years who do not agree to the term of assent~* Patients who have started antineoplastic treatment~* Patients with syndromes and/or other systemic diseases associated with the diagnosis of lymphoid and acute myeloid leukemia~* Neoplasms other than lymphoid leukemia or acute myeloid

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Study group (Type: None): Composed of children/adolescent individuals who have a definitive diagnosis of lymphoid leukemia or acute myeloid leukemia, who will be invited to participate in the research, regardless of race or gender.
- Control group (Type: None): The control group is going to consist of healthy children/adolescent individuals, non-syndromic, without history of cancer, matched by age and gender in relation to the study group, who have not used antibiotics 48 hours before or in the day of evaluation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Relevance of Gastric Aspirate in HCMV Detection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria of the newborn:~- Child born in maternity and / or child hospitalized in the Neonatal Médicine Department of the University Hospital of Besançon for which a urine sample (minimum volume = 0.5 mL) and a gastric aspiration fluid sample (minimum volume = 0.7mL) were collected (regardless of gender, birth weight or pathology presented at admission).~Exclusion Criteria of the newborn:~* Child died before the sampling~* A volume of gastric aspiration fluid dedicated to the study less than 0.7 mL.~* An impossible collection of urine (malformation, skin irritation of the perineum, contamination with meconium).

- Gender: ALL
- Minimum Age: 1 Minute
- Maximum Age: 7 Days
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Examining the Effects of Processed Music on Chronic Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must self-report as suffering from chronic pain~Exclusion Criteria:~* Individuals who do not read or speak proficient English~* Individuals with substantial, uncorrected hearing loss

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): This group will listen to 1 hour of processed music (Safe and Sound Protocol) for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathological diagnosis of Advanced biliary malignancy~* The expected survival period is ≥3 months~* Patients with non-extensive metastases~* Except for the lesions to be radiotherapy, there is at least one measurable lesion~* tumor lesions are suitable for radiotherapy~* Have previously received platinum, gemcitabine or 5-FU drugs as first-line treatment, but have not used PD-1/PD-L1 monoclonal antibody treatment~* In the 7 days before enrollment, the Child Pugh score of liver function is 7 or less~Exclusion Criteria:~* Patients with other malignant tumors~* Participated in other drug clinical trials within four weeks~* Clinical diagnosis of severe biliary obstruction or digestive tract obstruction in the past month~* Unstable angina pectoris~* Immunodeficiency~* Infectious pneumonia, non-infectious pneumonia, interstitial pneumonia~* Patients who need to use corticosteroids~* Serious chronic autoimmune diseases~* Ulcerative enteritis, Crohn's disease and other inflammatory bowel diseases~* Inflammatory and chronic diarrheal diseases such as irritable bowel syndrome;~* Sarcoidosis or tuberculosis~* Patients with hypersensitivity to human or murine monoclonal antibodies~* Pregnant and lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- tislelizumab combined with radiotherapy (Type: EXPERIMENTAL): To observe and evaluate the effectiveness and safety of tislelizumab combined with radiotherapy in the treatment of patients with advanced biliary malignancies.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study Evaluating the Use of PROSPECT to Reduce Insomnia in Patients With Early Stage Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical diagnosis of insomnia as identified through the screening Insomnia Severity Index score \>14~2. Insomnia present for \> 30 days per patient report~3. Female gender~4. Histologically proven stage 0-III invasive carcinoma of the breast~   a. Patient's must have completed primary surgical resection at least 2 weeks prior to enrollment, radiation at least 2 weeks prior to enrollment and/or cytotoxic chemotherapy at least 6 weeks prior to enrollment in the study~5. ECOG performance status 0-2~6. Ability to operate the accelerometer (Actiwatch Spectrum Pro)~7. The patient is aware of the nature of her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent document~Exclusion Criteria:~1. Subjects who do not have access to the internet to use the internet-based module, PROSPECT~2. Initiation of hormone therapy \<4 weeks prior to enrollment in the study~3. Initiation of sleep aids, including over-the-counter or prescription medications taken for insomnia (melatonin, benzodiazepines, antihistamines, etc.) for \< 4 weeks prior to enrollment in the study~4. Use of medication for treatment of another sleep disorder, such as restless leg syndrome or narcolepsy~5. History of medial or arthritic disease that could confound or interfere with evaluation of activity level, including but not limited to inflammatory arthritis (Rheumatoid Arthritis, Systemic Lupus Spondyloarthropathy, Psoriatic Arthritis, Polymyalgia Rheumatica), Parkinson's disease and cancer involving the bone~6. Second or third shift workers or others with non-traditional sleep schedules~7. Serious or unstable medical condition that could likely lead to hospitalization during the course of the study or compromise study participation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PROSPECT (Type: EXPERIMENTAL): Participants who have received treatment for early stage breast cancer and who experience chronic insomnia as assessed by difficulty sleeping for \>30 days with an insomnia severity index score of \>14. Participants will complete baseline symptom questionnaires and actigraphy, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 6 weeks. Participants will then repeat questionnaires and actigraphy at 6 weeks and questionnaires at 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ritalin: Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced phase of neoplasm without any treatment available.~* Life expectancy of more than 1 month~* Karnofsky index more than 50%~* Chemotherapy IV or immunotherapy SC stopped more than 3 weeks before the end of the study~* Asthenia more than 5/10 on the visual analogical scale~* Informed consent form signed~* Affiliation to social security~Exclusion Criteria:~* Patients who can receive chemotherapy IV or immunotherapy SC in the month following the study~* Patients in whom disease can respond to chemotherapy~* Corticotherapy started less than 7 days before the study or potentially within the first week of the study~* Asthenia which can be easily corrected~* Contraindications to the amphetamines~* HADS score of anxiety and/or depression more than or egal to 17/21~* Potential surgery with general anesthesia in the first 7 days of the study~* Inability to quantify the sensation of asthenia on the visual analogical scale~* Pregnancy or feeding~* Guardianship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): methylphenidate at 20mg per day during 7 days, at 20mg or 40mg per day during 7 days and 20, 40 or 60mg per day during 14 days
- 2 (Type: PLACEBO_COMPARATOR): placebo capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Calciuric Effect and Cyclic Parenteral Nutrition in Preterm Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Preterm babies with birth weights of 1500 gm or less.~* Expected to be restricted from oral feeding or on trophic feeds~* On TPN for at least 6 days~Exclusion Criteria:~* Infants who at the time of enrollment are on any diuretics (Lasix, hydrochlorothiazide, Aldactone, etc.) or caffeine~* those who are hemodynamically unstable~* Or have renal or hepatic insufficiency~* Infants with major congenital anomalies

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 9 Months
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects \>65 years of age at the time of signing the informed consent form~2. A confirmed diagnosis of AML according to the 2008 WHO classification~   * This includes: Bone marrow aspirate with a good clot or biopsy for morphology, flow cytometry, cytogenetic analysis, and in case of normal cytogenetics, molecular genetic analyses including FLT3-ITD, NPM-1 and CEBP A~  * Bio-banking of leukemic cells at diagnosis performed (according to guidelines of the Swedish National AML biobank).~3. A documented CR or CRp achieved after one or two induction courses.~Exclusion Criteria:~1. Subjects who are not considered to be candidates to complete the consolidation therapy due to medical or psychological reasons.~2. Subjects who have taken any investigational drugs or participated in an interventional clinical trial within 30 days prior to screening.~3. Patients with acute promyelocytic leukemia~4. Patients with t(8;21) or inv(16)~5. CNS leukemia~6. Patients with a previous diagnosis of MDS, i.e. AML preceded by a diagnosed MDS~7. Subjects who are candidates for allogeneic stem cell transplantation (SCT)~8. Another cancer diagnosis with a life expectancy of less than two years

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azacitidine (Type: EXPERIMENTAL): Azacitidine 75mg/m2/d subcutaneously once daily for 5 days given every 5:th week for 8 cycles.
- DA (Type: ACTIVE_COMPARATOR): Two courses of DA in accordance with the Swedish National treatment program (reduced doses):~In case one induction course was given:~First consolidation course: daunorubicin 45 mg/m2 x 1 (iv infusion) day 1-3 and cytarabine 1000 mg/m2 x 2 (iv infusion) day 1-4.~Second consolidation course: daunorubicin 45 mg/m2 x 1( iv infusion) day 1-2 and cytarabine 200 mg x 2 (fixed dose sc injection) day 1- 5.~In case two induction courses were given:~First consolidation course: daunorubicin 45 mg/m2 x 1( iv infusion) day 1-2 and cytarabine 200 mg x 2 (fixed dose sc injection) day 1- 5.~Second consolidation course: cytarabine 200mg x 2 (fixed dose sc injection) day 1-5.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MUCOviscidose EXacerbation Outils Connectés Education Thérapeutique

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 12 years and over~* Cystic fibrosis confirmed by sweat test or genetic~* Able to understand and respect the protocol and its requirements~* Who signed the consent prior to any other procedure protocolFollowed in the same CF center during the study~* In clinically stable condition - no pulmonary exacerbation requiring intravenous antibiotics - in the previous 4 weeks)~* Prescribed at least one pulmonary medication (eg, inhaled mucolytic, inhaled or oral antibiotic therapy, hypertonic saline)~* Not undergone solid organ transplants~* With smartphone, computer or tablet connected to wifi access~Exclusion Criteria:~* Patient undergoing solid organ transplant~* Pregnancy or planned pregnancy during the period of the study~* Patient on exclusion period because of other clinical research esearch~* Patients who don't use connected devices during the 3 first months will be excluded from the study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Refusal Group (Type: OTHER): Refusal Questionnaires Intervention:~Clinic staff will email all patients or parents (pediatric settings) to introduce the study. A qualitative interview with 10 patients who declined to participate in the study will be conducted to identify the reason of refusal.
- Interventionnal Group (Type: OTHER): Connected Devices for 3 months (36 patients will be equipped with CDs-spirometer, oxymeter, scales, podometer watch and AURA device for sleep quality and analyze) Educationnal Intervention Connected Devices for 12 months Interviews

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues